Physician profile
Michelle Cho
NPI 1730349192
$3,422.16
in general payments reported to CMS, 2019-2025
28 companies · $976 in 2025
The $976 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $263 · 2021: $285 · 2022: $122 · 2023: $583 · 2024: $714 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,156 · Education: $87.70 · Travel and Lodging: $29.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,155.85 |
| Education | $87.70 |
| Travel and Lodging | $29.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $678.36 | 2020-2025 | Centurion, Tryptyr, Clareon |
| Abbvie INC. | $557.01 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Glaukos Corporation | $318.05 | 2021-2024 | Ce-Marked Kxla System, Kxl System (Not Refurbished) |
| Mallinckrodt Hospital Products INC. | $252.54 | 2021-2025 | Acthar |
| Dompe US, INC. | $186.78 | 2019-2025 | Oxervate |
| Allergan, INC. | $177.69 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $169.96 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $162.89 | 2019-2025 | Cequa |
| Rayner Intraocular Lenses Limited | $110.83 | 2023-2025 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Kala Pharmaceuticals, INC. | $109.74 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $109.58 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $93.05 | 2020-2023 | |
| Oyster Point Pharma, INC. | $76.01 | 2022-2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $56.28 | 2024-2025 | Vyzulta, Miebo, Xiidra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $29.57 | 2025 | Proclaim |
| Boston Scientific Corporation | $28.77 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $23.78 | 2019 | |
| Ani Pharmaceuticals, INC. | $22.39 | 2025 | Purified Cortrophin Gel |
| Biogen, INC. | $20.80 | 2020 | |
| Shire North American Group INC | $20.59 | 2019 | |
| Apellis Pharmaceuticals, INC. | $19.46 | 2024 | Syfovre |
| Rxsight INC | $19.32 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Ocular Therapeutix, INC. | $19.04 | 2022 | |
| Amgen INC. | $18.13 | 2024 | Tepezza |
| Harrow Eye, LLC | $15.48 | 2024 | Vevye |
| Aerie Pharmaceuticals, INC. | $13.06 | 2019 | |
| Akorn, INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.